Sicart Associates’s AbbVie ABBV Stock Holding History

Sicart Associates’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-30,734	Closed	-$1.93M	–	88
2016 Q4	$1.93M	Buy	+30,734	New	+$1.88M	1.33%	26

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Sicart Associates's ABBV Position: Q1 2017 in Review

Sicart Associates sold out of AbbVie (ABBV) in Q1 2017, closing a stake of 30,734 shares — an estimated $1.93M sold.

Sicart Associates first reported a position in ABBV in Q4 2016 and held it in 1 quarter. The position peaked at $1.93M in Q4 2016. 1,727 funds tracked by Wall St. Rank hold ABBV as of Q1 2017.

Sicart Associates reported no remaining AbbVie position as of Q1 2017 after selling out during the quarter.
Sicart Associates sold 30,734 AbbVie shares in Q1 2017, an estimated $1.93M.
Sicart Associates first reported a position in AbbVie in Q4 2016 and held it in 1 quarter.
Sicart Associates's AbbVie position peaked at $1.93M in Q4 2016.
1,727 funds tracked by Wall St. Rank held AbbVie as of Q1 2017.

Based on Sicart Associates's 13F filing for Q1 2017, filed 10 Apr 2017.